Precision Biosciences (DTIL) Total Liabilities (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Total Liabilities of $67.8 million for Q1 2026, down 9.7% year-over-year from $75.1 million in Q1 2025, and up 9.04% quarter-over-quarter from $62.2 million in Q4 2025.
Precision Biosciences (DTIL) Total Liabilities (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Total Liabilities for 9 consecutive years, with $67.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 9.7% year-over-year to $67.8 million; the TTM figure through Mar 2026 stood at $67.8 million (down 9.7% YoY), while the FY2025 annual figure was $62.2 million, down 22.29% from the prior year.
- Total Liabilities rose to $67.8 million in Q1 2026 per DTIL's latest filing, from $62.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $194.1 million in Q2 2022 and bottomed at $62.2 million in Q4 2025.
- Historically, Total Liabilities has averaged $119.0 million across 5 years, with a median of $111.7 million in 2022.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 49.84% — and 2025, when it tumbled 49.11%.
- Precision Biosciences' Total Liabilities stood at $177.7 million in 2022, then declined by 20.71% to $140.9 million in 2023, then sank by 43.23% to $80.0 million in 2024, then dropped by 22.29% to $62.2 million in 2025, then rose by 9.04% to $67.8 million in 2026.
- Business Quant data shows DTIL's Total Liabilities at $67.8 million in Q1 2026, $62.2 million in Q4 2025, and $76.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 10.03 Bn |
| 10 | Precision Biosciences | 224.82 Mn | 137.27 Mn | - | 80.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.63 Mn |
| Mar 31, 2026 | 67.79 Mn |
| Dec 31, 2025 | 62.17 Mn |
| Sep 30, 2025 | 76.88 Mn |
| Jun 30, 2025 | 74.87 Mn |
| Mar 31, 2025 | 75.07 Mn |
| Dec 31, 2024 | 80.00 Mn |
| Sep 30, 2024 | 88.39 Mn |
| Jun 30, 2024 | 91.09 Mn |
| Mar 31, 2024 | 147.54 Mn |
| Dec 31, 2023 | 140.92 Mn |
| Sep 30, 2023 | 135.28 Mn |
| Jun 30, 2023 | 147.66 Mn |
| Mar 31, 2023 | 164.33 Mn |
| Dec 31, 2022 | 177.74 Mn |
| Sep 30, 2022 | 187.35 Mn |
| Jun 30, 2022 | 194.14 Mn |
| Mar 31, 2022 | 111.69 Mn |
| Dec 31, 2021 | 120.33 Mn |
| Sep 30, 2021 | 125.76 Mn |